drugset / Trial / NCT00216827

Efficacy and Safety of Calcipotriol Plus Betamethasone Gel in the Treatment of Scalp Psoriasis

NCT00216827

Phase 3 Completed 1485 enrolled LEO Pharma
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate whether once daily treatment for up to 8 weeks of calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) gel is safe and more effective than betamethasone 0.5 mg/g (as dipropionate) in the gel vehicle, calcipotriol 50 mcg/g in the gel vehicle or the gel vehicle used alone in patients with scalp psoriasis. The primary outcome is the proportion of patients with absence of disease or very mild disease after 8 weeks of treatment.

Timeline

Start
2004-11
Primary completion
Completion
2005-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Calcipotriol Small molecule 50 unknown
Subject betamethasone dipropionate Small molecule 0.5 unknown

Indications